IN2015DN00542A - - Google Patents

Info

Publication number
IN2015DN00542A
IN2015DN00542A IN542DEN2015A IN2015DN00542A IN 2015DN00542 A IN2015DN00542 A IN 2015DN00542A IN 542DEN2015 A IN542DEN2015 A IN 542DEN2015A IN 2015DN00542 A IN2015DN00542 A IN 2015DN00542A
Authority
IN
India
Prior art keywords
compositions
disorders
methods
treating
diseases
Prior art date
Application number
Other languages
English (en)
Inventor
Wei Wei Chang
Kenneth Sawyer
Original Assignee
Rhodes Technologies
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhodes Technologies filed Critical Rhodes Technologies
Publication of IN2015DN00542A publication Critical patent/IN2015DN00542A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/04Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
IN542DEN2015 2012-07-27 2013-07-26 IN2015DN00542A (enrdf_load_stackoverflow)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261676530P 2012-07-27 2012-07-27
US201361756321P 2013-01-24 2013-01-24
PCT/US2013/052264 WO2014018856A1 (en) 2012-07-27 2013-07-26 Compositions and treatment for eye diseases and disorders

Publications (1)

Publication Number Publication Date
IN2015DN00542A true IN2015DN00542A (enrdf_load_stackoverflow) 2015-06-26

Family

ID=49997851

Family Applications (1)

Application Number Title Priority Date Filing Date
IN542DEN2015 IN2015DN00542A (enrdf_load_stackoverflow) 2012-07-27 2013-07-26

Country Status (20)

Country Link
US (2) US20150216877A1 (enrdf_load_stackoverflow)
EP (1) EP2877184B1 (enrdf_load_stackoverflow)
JP (1) JP6209777B2 (enrdf_load_stackoverflow)
KR (1) KR102097663B1 (enrdf_load_stackoverflow)
CN (2) CN104661663A (enrdf_load_stackoverflow)
AU (1) AU2013295645B2 (enrdf_load_stackoverflow)
BR (1) BR112015001847A8 (enrdf_load_stackoverflow)
CA (1) CA2880027C (enrdf_load_stackoverflow)
DK (1) DK2877184T3 (enrdf_load_stackoverflow)
ES (1) ES2759781T3 (enrdf_load_stackoverflow)
HU (1) HUE046963T2 (enrdf_load_stackoverflow)
IL (1) IL236920B (enrdf_load_stackoverflow)
IN (1) IN2015DN00542A (enrdf_load_stackoverflow)
MX (1) MX362185B (enrdf_load_stackoverflow)
NZ (1) NZ704247A (enrdf_load_stackoverflow)
PL (1) PL2877184T3 (enrdf_load_stackoverflow)
PT (1) PT2877184T (enrdf_load_stackoverflow)
SM (1) SMT201900678T1 (enrdf_load_stackoverflow)
WO (1) WO2014018856A1 (enrdf_load_stackoverflow)
ZA (1) ZA201500561B (enrdf_load_stackoverflow)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
HUE034886T2 (hu) 2013-03-15 2018-03-28 Glia Llc Gyógyszerek cranialis adagolása
WO2015080758A1 (en) * 2013-11-27 2015-06-04 Al-Qahtani Ahmed H Method and composition for the treatment of moderate to severe keratoconjunctivitis sicca
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. 天然の併用ホルモン補充療法剤及び療法
CA2956919C (en) 2014-07-21 2022-07-19 Glia, Llc Method for treating radiotherapy- and chemotherapy-associated cognitive or emotional impairment with cannabinoids
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019513709A (ja) 2016-04-01 2019-05-30 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. ステロイドホルモン薬学的組成物
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR101960023B1 (ko) * 2016-12-21 2019-03-20 김보경 이산화탄소 발생 장치
CA3167771A1 (en) * 2020-02-12 2021-08-19 Glia, Llc Progesterone combinations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102656A (en) 1983-07-29 1992-04-07 The Mennen Company Antiperspirant creams
US4937069A (en) 1985-11-15 1990-06-26 Bristol-Myers Squibb Company Anhydrous semi-solid antiperspirant suspension
US5069897A (en) 1987-10-16 1991-12-03 The Proctor & Gamble Company Antiperspirant creams
US6659985B2 (en) 2002-01-30 2003-12-09 Southern College Of Optometry Method to use transdermal administration of androgens to the adnexa of the eye
US7572780B2 (en) * 2003-01-21 2009-08-11 Dimera, Incorporated Method and kit for reducing the symptoms of peripheral vascular disease
US20080132475A1 (en) 2006-12-05 2008-06-05 Charles Gerald Connor Treatment for dry eye
NZ584275A (en) * 2007-10-08 2012-06-29 Fovea Pharmaceuticals Aqueous cyclosporine ophthalmic formulations
US20100016264A1 (en) 2007-12-05 2010-01-21 Connor Charles G Treatment for dry eye using testosterone and progestagen
CN101757622A (zh) * 2008-11-28 2010-06-30 天津金耀集团有限公司 一种眼部抗炎的药物组合物
CA2776471C (en) * 2009-10-02 2019-02-12 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses

Also Published As

Publication number Publication date
CA2880027C (en) 2021-12-07
US9925201B2 (en) 2018-03-27
BR112015001847A8 (pt) 2021-09-08
EP2877184B1 (en) 2019-09-04
EP2877184A1 (en) 2015-06-03
DK2877184T3 (da) 2019-12-09
HUE046963T2 (hu) 2020-04-28
MX362185B (es) 2019-01-08
IL236920B (en) 2018-06-28
CN107595857A (zh) 2018-01-19
KR102097663B1 (ko) 2020-04-06
CA2880027A1 (en) 2014-01-30
MX2015001250A (es) 2015-10-22
SMT201900678T1 (it) 2020-03-13
NZ704247A (en) 2018-04-27
CN104661663A (zh) 2015-05-27
BR112015001847A2 (pt) 2017-07-04
PL2877184T3 (pl) 2020-04-30
KR20150038311A (ko) 2015-04-08
WO2014018856A1 (en) 2014-01-30
AU2013295645B2 (en) 2017-08-24
JP6209777B2 (ja) 2017-10-11
ZA201500561B (en) 2016-04-28
US20150216877A1 (en) 2015-08-06
AU2013295645A1 (en) 2015-02-05
ES2759781T3 (es) 2020-05-12
EP2877184A4 (en) 2016-03-30
HK1210968A1 (en) 2016-05-13
PT2877184T (pt) 2019-12-02
JP2015524434A (ja) 2015-08-24
US20170189413A1 (en) 2017-07-06

Similar Documents

Publication Publication Date Title
IN2015DN00542A (enrdf_load_stackoverflow)
EP3185876A4 (en) Compositions and methods for treatment of neurological disorders
EP4324527A3 (en) Formulations of enzalutamide
MX365294B (es) Inhibidores de proteína cinasa dependiente de adn.
EP2709672A4 (en) COMPOSITIONS AND METHODS FOR TREATING NETWORK GLAND DISEASES
EP3174894A4 (en) Compositions and methods of use for treating metabolic disorders
EP3024497A4 (en) Methods and compositions for treating brain diseases
HK1216175A1 (zh) 治療性化合物和組合物
EP3160493A4 (en) Compositions and methods to regulate renalase in the treatment of diseases and disorders
EP3182977A4 (en) Compositions and methods to treat vision disorders
EP3515444A4 (en) COMPOSITION FOR TREATING EYE DISEASES AND METHOD FOR USE AND PRODUCTION
EP3086809A4 (en) Compositions and methods of treating ocular diseases
EP2782566A4 (en) L-SERIN COMPOSITIONS, METHODS AND USES FOR TREATING NEURODEEGENERATIVE ILLNESSES AND SUFFERING
EP3082427A4 (en) Compositions and methods for treatment of glaucoma
EP3370709A4 (en) USE OF PROTEASOME INHIBITORS FOR THE TREATMENT OF EYE DISEASES
PH12016500495A1 (en) Compositions for the treatment of hypertension and/or fibrosis
GB201213484D0 (en) Pharmaceutical compositions comprising 15-OHEPA and methods of using the same
EP2847169A4 (en) COMPOSITIONS AND METHODS FOR TREATING NEUROLOGICAL DISORDERS
EP3265103A4 (en) Compositions and methods for treating ocular diseases
PH12017501694A1 (en) Compositions for the treatment of fibrosis and fibrosis-related diseases
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
EP3129054A4 (en) Methods and compositions for the treatment of ocular diseases and disorders
EP3003341A4 (en) Compositions and methods for treatment of retinal degenerative diseases
HK40092664A (en) Compositions and methods for treatment of neurological disorders
HK40066377A (en) Compositions and methods for treatment of neurological disorders